¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"malignant jaundice of dogs"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • malignant teratoma
    ¾Ç¼º±âÇüÁ¾
  • malignant transformation
    ¾Ç¼ºÀüȯ
  • malignant tumor
    ¾Ç¼ºÁ¾¾ç
  • neuroleptic malignant syndrome
    ½Å°æÀÌ¿ÏÁ¦¾Ç¼ºÁõÈıº
  • acholuric familial jaundice
    ¹«´ãÁó´¢°¡Á·¼ºÈ²´Þ
  • acholuric jaundice
    ¹«´ãÁó´¢È²´Þ
  • blue jaundice
    ûȲ´Þ
  • breast milk jaundice
    ¸ðÀ¯È²´Þ
  • cholangitic jaundice
    ´ã°ü¿°È²´Þ, ¾µ°³°ü¿°È²´Þ
  • cholestatic jaundice
    ´ãÁóÁ¤Ã¼È²´Þ, ¾µ°³ÁóÁ¤Ã¼È²´Þ
  • drug-induced jaundice
    ¾à¹°À¯¹ßȲ´Þ
  • epidemic jaundice
    À¯ÇàȲ´Þ
  • green jaundice
    ³ì»öȲ´Þ
  • hemapheic jaundice
    ¿ì·Îºô¸°È²´Þ
  • hematohepatogenous jaundice
    Ç÷¾×°£¼ºÈ²´Þ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • nonhemolytic jaundice
    ºñ¿ëÇ÷Ȳ´Þ
  • nuclear jaundice
    (¢¡kernicterus) ÇÙȲ´Þ
  • obstructive jaundice
    Æó¼âȲ´Þ
  • regurgitation jaundice
    ¿ª·ùȲ´Þ
  • retention jaundice
    ü·ùȲ´Þ
  • toxemic jaundice
    Áßµ¶È²´Þ
  • urobilin jaundice
    ¿ì·Îºô¸°È²´Þ
  • malignant anemia
    (¢¡pernicious anemia) ¾Ç¼ººóÇ÷
  • borderline malignant epithelial ovarian neoplasm
    °æ°è¾Ç¼º»óÇdz­¼ÒÁ¾¾ç
  • malignant carcinoid
    ¾Ç¼ºÄ«¸£½Ã³ëÀ̵å, ¾Ç¼ºÀ¯¾ÏÁ¾
  • malignant change
    ¾Ç¼ºº¯È­
  • malignant cholera
    ¾Ç¼ºÄÝ·¹¶ó
  • malignant degeneration
    ¾Ç¼ºº¯¼º
  • malignant reticulemic erythroderma
    ¾Ç¼º¸Á»óÈ«»öÇǺÎÁõ
  • malignant hidradenoma
    ¾Ç¼º¶¡»ùÁ¾
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • infectious jaundice =Weil s disease
    Àü¿°¼º Ȳ´Þ.
  • precocious jaundice ³ª icterus praecox
    Á¶¹ßȲ´Þ(¡­üÜÓ¸).
  • recurrent jaundice of pregnancy
    ¹Ýº¹¼º Àӽżº(ÚãÜÖàõìôããàõ)Ȳ´Þ.
  • recurrent jaundice of pregnancy
    ¹Ýº¹¼º ÀӽżºÈ²´Þ(ÚãÜÖàõìôããàõüÜÓ¸)
  • regurgitation jaundice
    ¿ª·ù¼º Ȳ´Þ(¡­¼ºÈ²´Þ).
  • regurgitation jaundice
    ¿ª·ù¼º Ȳ´Þ(æ½×µàõüÜÓ¸)
  • renal dissociation jaundice
    ½ÅÇØ¸®¼º Ȳ´Þ(ãìú°ìÆàõüÜÓ¸).
  • renal dissociation jaundice
    ½ÅÇØ¸®¼º Ȳ´Þ(ãìú°ìÆàõüÜÓ¸)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • congenital nonhemolytic jaundice
    ¼±Ãµ¼º ºñ¿ëÇ÷¼º Ȳ´Þ(ËÛ̧ËÛ?ËíÌ´ËÛÌ·ËÀ ).
  • epidemic jaundice
    À¯Ç༺ Ȳ´Þ
  • extrahepatic jaundice
    °£¿Ü¼º Ȳ´Þ(ÊÜèâàõüÜÓ¸).
  • extrahepatic obstructive jaundice
    °£¿ÜÆó¼â¼º Ȳ´Þ(ÊÜèâøÍáðàõüÜÓ¸).
  • familial hemolytic jaundice
    °¡Á·¼º ¿ëÇ÷¼º Ȳ´Þ.
  • familial nonhemolytic jaundice
    °¡Á·¼º ºñ¿ëÇ÷¼º Ȳ´Þ.
  • flavin jaundice
    ÇöóºóȲ´Þ.
  • green jaundice<³ª> icterus viridans
    ³ì»öȲ´Þ(ÖàßäüÜÓ¸).
  • hemapheic jaundice =urobilin j.
    ¿ì·Îºô¸°¼º Ȳ´Þ(¡­üÜÓ¸).
  • hematohepatogenous jaundice
    Ç÷¾×°£¼º Ȳ´Þ.
  • hemolytic jaundice
    ¿ëÇ÷¼º Ȳ´Þ.
  • hemorrhagic jaundice
    ÃâÇ÷(¼º) Ȳ´Þ.
  • hepatic dissociation jaundice
    °£Çظ®¼º Ȳ´Þ.
  • hepatocellular jaundice
    °£¼¼Æ÷¼º Ȳ´Þ.
  • homologous serum jaundice
    µ¿·ùÇ÷û¼º Ȳ´Þ.
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • malignant polyp
    ¾Ç¼ºÆú¸³
  • malignant tumor
    ¾Ç¼ºÁ¾¾ç
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
jaund jaundice
131I radioactive Iodine(used in Thyroid uptake, Liver & Kidney Scans & Treatment of malignant & nonmalig...
MFH Malignant Fibrous Histocytoma
MH Malignant Hyperthermia
NMS Neuroleptic Malignant Syndrome
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
MEO Malignant External Otitis
MFH malignant fibrous histocytoma
MH Malignant Histiocytosis
MH Malignant Hyperpyrexia
MH Malignant Hyperthermia
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • malignant adenoma
    ¾Ç¼º ¼±Á¾
  • malignant anthrax
    ¾Ç¼º źÀú
  • malignant cachexia
    ¾Ç¼º ¾Ç¾×Áú
  • malignant carcinoid tumor
    ¾Ç¼º Ä«¸£½Ã³ëÀ̵å Á¾¾ç
  • malignant degeneration
    ¾Ç¼ºÈ­
  • malignant external otitiis
    ¾Ç¼º ¿ÜÀÌ¿°
    ´ç´¢º´ ȯÀÚ³ª ¿©·¯ °¡Áö ¿øÀÎÀ¸·Î ¸é¿ª Àå¾Ö ȯÀڵ鿡¼­ ¿ÜÀ̵µ¿°ÀÌ ÁøÇàµÇ¾î µÎ°³ÀúÀÇ °ñ¼ö¿°¿¡ À̸£°Ô µÇ´Âµ¥ À̸¦ ¾Ç¼º ¿ÜÀÌ¿°À̶ó ÇÑ´Ù. ¿øÀαÕÀº Pseudomonas aeruginosaÀÌ¸ç ¿ÜÀ̵µÀÇ ¹Ù´Ú ºÎÀ§¿¡¼­ ±â½ÃÇÏ¿© Áߵΰ³Àú¿Í clivus, ½ÉÁö¾î´Â ¹Ý´ëÂÊÀÇ µÎ°³Àú¿¡ À̸£±âµµ ÇÑ´Ù. ȯÀÚµéÀº ´ë°³ ¾ÇÃë°¡ ³ª´Â ÀÌ·ç¿Í ÇÔ²² ¿ÜÀ̵µ¿¡´Â À°¾ÆÁ¶Á÷ÀÌ °üÂûµÇ°í ±íÀº ºÎÀ§ÀÇ ÀÌÅëÀ» È£¼ÒÇÑ´Ù. Áø´ÜÀº CT ÃÔ¿µÀ̳ª, ¹æ»ç¼± µ¿À§¿ø¼Ò¸¦ ÀÌ¿ëÇÑ °ñ ÁÖ»ç
  • malignant granuloma
    ¾Ç¼º À°¾ÆÁ¾
    ¾Ç¼º ¸²ÇÁÁ¾, º£°Ô³Ê À°¾ÆÁ¾°ú ´Ù¸£Áö¸¸ ±× º´ ÀÚü°¡ ¹àÇôÁöÁö ¾Ê¾Æ Á¾¾ç ¿©ºÎ Á¶Â÷µµ È®½ÇÇÏÁö ¾ÊÀºµ¥, ±«»ç¼º º´º¯ÀÌ ³Ê¹« °­ÇϹǷΠº´¸®Á¶Á÷ÇÐÀû °Ë»öµµ °ï¶õÇÏ´Ù. Àü½Å¼º ÀüÀÌ´Â ÀûÀ¸³ª ±¹¼ÒÀû ±«»ç ÁøÇàÀÌ ´ë´ÜÈ÷ ºü¸£°í ¼¼±Õ °¨¿°À» ÀÏÀ¸Å°±â ½¬¿ì¸ç ÆÐÇ÷Áõ°ú À¯»çÇÑ °£Çæ ¿­°ú °í¿­ÀÌ ÀϾ Àü½ÅÀÌ ¼è¾àÇØÁö°í ¿¹Èİ¡ ³ª»Ú´Ù.
  • malignant hemocytoblastoma
    ¾Ç¼º Ç÷±¸¸ð¼¼Æ÷Á¾
  • malignant hyperthermia
    ¾Ç¼º °í¿­Áõ, ¾Ç¼º °í¿­
    ¸¶Ãë Áß¿¡ °©ÀÚ±â °í¿­À» ³»°í »ç¸Á·üÀÌ ±ØÈ÷ ³ôÀº ÁõÈıº¿¡ ´ëÇÏ¿© À̸§ÀÌ ºÙ¿©Áø °ÍÀÌ´Ù. Áõ»óÀº È£ÈíÀ̳ª ¸Æ¹ÚÀÌ »¡¶óÁö°í ü¿ÂÀº 5ºÐ¿¡ 1¡É Á¤µµÀÇ ¼Óµµ·Î 42¡É¿¡³ª ´ÞÇÑ´Ù. µ¿½Ã¿¡ ±ÙÀÇ °æÁ÷À̳ª °ú±äÀåÀÌ »ý±â°í ´ë»ç¼º ¹× È£Èí¼º »êÁõ, °íÄ®·ýÇ÷ÁõÀÌ ³ªÅ¸³­´Ù. ±Ù°æÁ÷¼º À§Ãà, À¯ÀüÀÚ ÀÎÀÚ
  • malignant hyperthermia syndrome
    ¾Ç¼º °í¿­ ÁõÈıº
  • malignant lesion
    ¾Ç¼º º´¼Ò
  • malignant melanoma
    ¾Ç¼º Èæ»öÁ¾
    1. ¿ÜÀ½¿¡ »ý±â´Â °¡Àå Áß¿äÇÑ º´º¯ÀÎ Á¾¾çÀÇ ÀÏÁ¾À¸·Î ¿ÜÀ½ÀÇ ¾Ç¼º Èæ»öÁ¾Àº µå¹°°í, ¿©¼º¿¡¼­ °üÂûµÇ´Â Èæ»öÁ¾ÀÇ 2%°¡ ¿ÜÀ½¿¡¼­ ¹ß»ýÇÑ´Ù. 2. »ö¼Ò ¼¼Æ÷¿¡ »ý±ä ¾Ç¼º Á¾¾ç. 3. Ç¥ÇǼº Èæ»ö±¸¿Í ±× Àü±¸Ã¼·ÎºÎÅÍ ¹ß»ýÇÏ´Â ´ë´ÜÈ÷ ¾Ç¼ºÀÎ Á¾¾çÀÌ´Ù. ¸ðµç ¾Ç¼º Á¾¾ç Áß 1%°¡ ¾Ç¼º Èæ»öÁ¾ÀÌ´Ù. ÀÌÁß 90%´Â ¿ÜÇÇ¿¡ ³ªÅ¸³ª°í 10%´Â ÇǺΠ¿Ü¿¡ ³ªÅ¸³­´Ù. ¸ðµç ¾Ç¼º Èæ»öÁ¾ Áß 1%´Â ±¸°­ ³»¿¡¼­ ¹ß»ýÇÑ´Ù. ¹ß»ýÀ²ÀÌ Áõ°¡µÇ´Â °Íó·³ º¸ÀÌ´Â ÀÌ·± Á¾¾çÀÇ Æ¯È÷ ³ª»Û Á¡Àº ¸²ÇÁ ¼øÈ¯°ú Ç÷¾× ¼øÈ¯À» ÅëÇØ ºü¸£°Ô ÀüÀ̵Ǵ °ÍÀÌ´Ù.
  • malignant mesenchymoma
    ¾Ç¼º ³»¹è¿±Á¾
  • malignant myopia
    ¾Ç¼º ±Ù½Ã
    Ã༺ ±Ù½Ã·Î¼­ ¾ÈÃàÀåÀÌ ±¼Àý·Â¿¡ ºñÇØ ³Ê¹« ±æ¾î ÆòÇà ±¤¼±ÀÌ ¸Á¸· ¾Õ¿¡ ÃÊÁ¡À» ¸ÎÀ¸¹Ç·Î ¼±¸íÇÏÁö ¾ÊÀº »óÀ» ¸Î°Ô µÈ´Ù. °úµµÇÑ Á¶Àý ¹× ´« ¸ðÀ½, ½Ã½Å°æ À¯µÎÀÇ ºÎÁ¾, ³»ºÐºñ ÀÌ»ó, Æí½Ä µîÀÌ ¿øÀÎÀ̶ó°í ÇÏ´Â ÁÖÀåµµ ÀÖÀ¸³ª ºÐ¸íÄ¡ ¾Ê´Ù.
  • malignant neoplasm
    ¾Ç¼º ½Å»ý¹°
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
chronic idiopathic jaundice <syndrome> An inherited disorder (autosomal recessive) that is characterised by long-standing mild jaundice. This occurs secondary to an abnormality in the transport of bilirubin from the liver to the biliary system. This leads to an accumulation of bilirubin in the liver. Avoidance of alcohol and medications which can affect the liver is important.
Inheritance: autosomal recessive.
(27 Sep 1997)
physiologic jaundice Icterus which can be accentuated by many factors including excessive haemolysis, sepsis, neonatal hepatitis or congenital atresia of the biliary system.
Synonym: physiologic icterus, jaundice of the newborn, neonatal jaundice, physiologic jaundice.
(05 Mar 2000)
congenital haemolytic jaundice <haematology> A hereditary disorder that leads to a chronic haemolytic anaemia due to an abnormality in the red blood cell membrane.
This disorder is caused by a defective gene. Red cells are resistant to stress and rupture easily. Infants may appear jaundiced and pale. Fatigue, weakness and shortness of breath are other symptoms that may be seen in older patients. The spleen may also be enlarged.
Treatment includes splenectomy (removal of the spleen). After this is accomplished the life-span of the red blood cells returns to normal.
(27 Sep 1997)
postarsphenamine jaundice Liver toxicity, causing jaundice, in a patient who has received arsphenamine.
(05 Mar 2000)
haematogenous jaundice <haematology> Haemolytic jaundice is a type of jaundice, where the skin takes on a yellowish hue, which occurs when red blood cells have been destroyed (by haemolysis).
(09 Oct 1997)
haemolytic jaundice <haematology> Haemolytic jaundice is a type of jaundice, where the skin takes on a yellowish hue, which occurs when red blood cells have been destroyed (by haemolysis).
(09 Oct 1997)
hepatocellular jaundice Jaundice resulting from diffuse injury or inflammation or failure of function of the liver cells, usually referring to viral or toxic hepatitis.
(05 Mar 2000)
hepatogenous jaundice Jaundice resulting from disease of the liver, as distinguished from that due to blood changes.
(05 Mar 2000)
Schmorl's jaundice <paediatrics> Disorder due to jaundice in a newborn baby with high blood levels of the pigment bilirubin that is deposited in the brain resulting in damage. The level of bilirubin is monitored in newborns to determine whether treatment is needed to prevent kernicterus. With brain affected, it is also called bilirubin encephalopathy.
(12 Dec 1998)
homologous serum jaundice An obsolete term for viral hepatitis type B.
(05 Mar 2000)
human serum jaundice An obsolete name for hepatitis transmitted parenterally, usually by blood or blood products; usually due to hepatitis B.
(05 Mar 2000)
spherocytic jaundice Haemolytic jaundice associated with spherocytosis.
(05 Mar 2000)
spirochetal jaundice Jaundice caused by infection with Leptospira species, usually Leptospira icterohemorrhagica.
(05 Mar 2000)
neonatal jaundice Icterus which can be accentuated by many factors including excessive haemolysis, sepsis, neonatal hepatitis or congenital atresia of the biliary system.
Synonym: physiologic icterus, jaundice of the newborn, neonatal jaundice, physiologic jaundice.
(05 Mar 2000)
newborn jaundice <paediatrics> A normal condition of elevated bilirubin in the bloodstream of a newborn.
This occurs secondary to immaturity of liver cells (cannot effectively metabolise bilirubin) and the increased destruction of red blood cells (further releasing bilirubin into the bloodstream) that is normally seen in the newborn.
The jaundice usually appears between the 2nd and 5th days of life and usually clears by 2 weeks. Other factors which can potentiate jaundice in the newborn include: sepsis, biliary atresia, Rhesus incompatibility, galactosaemia, cephalohaematoma, polycythaemia, G-6-P-D deficiency and congenital rubella, syphilis, toxoplasmosis or cytomegalovirus infection.
(10 Jan 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á